Literature DB >> 24028840

Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.

Xianzhen Hu1, Rick A Wetsel2, Theresa N Ramos1, Stacey L Mueller-Ortiz2, Trenton R Schoeb3, Scott R Barnum4.   

Abstract

Carboxypeptidase N (CPN) is a member of the carboxypeptidase family of enzymes that cleave carboxy-terminal lysine and arginine residues from a large number of biologically active peptides and proteins. These enzymes are best known for their roles in modulating the activity of kinins, complement anaphylatoxins and coagulation proteins. Although CPN makes important contributions to acute inflammatory events, little is known about its role in autoimmune disease. In this study we used CPN(-/-) mice in experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis. Unexpectedly, we observed several EAE disease phenotypes in CPN(-/-) mice compared to wild type mice. The majority of CPN(-/-) mice died within five to seven days after disease induction, before displaying clinical signs of disease. The remaining mice presented with either mild EAE or did not develop EAE. In addition, CPN(-/-) mice injected with complete or incomplete Freund's adjuvant died within the same time frame and in similar numbers as those induced for EAE. Overall, the course of EAE in CPN(-/-) mice was significantly delayed and attenuated compared to wild type mice. Spinal cord histopathology in CPN(-/-) mice revealed meningeal, but not parenchymal leukocyte infiltration, and minimal demyelination. Our results indicate that CPN plays an important role in EAE development and progression and suggests that multiple CPN ligands contribute to the disease phenotypes we observed.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  CPN; CVF; Carboxypeptidase; Demyelinating disease; EAE; Kinins; MOG; MS/EAE; carboxypeptidase N; cobra venom factor; experimental autoimmune encephalomyelitis; myelin oligodendrocyte glycoprotein

Mesh:

Substances:

Year:  2013        PMID: 24028840      PMCID: PMC4339068          DOI: 10.1016/j.imbio.2013.08.007

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  27 in total

Review 1.  Kinin receptors in pain and inflammation.

Authors:  R Couture; M Harrisson; R M Vianna; F Cloutier
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

2.  Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.

Authors:  Kerstin Göbel; Susann Pankratz; Tilman Schneider-Hohendorf; Stefan Bittner; Michael K Schuhmann; Harald F Langer; Guido Stoll; Heinz Wiendl; Christoph Kleinschnitz; Sven G Meuth
Journal:  J Autoimmun       Date:  2011-01-08       Impact factor: 7.094

3.  Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein.

Authors:  Alexander J Szalai; Serge Nataf; Xian-Zhen Hu; Scott R Barnum
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

Review 4.  Carboxypeptidase N: a pleiotropic regulator of inflammation.

Authors:  Kirstin W Matthews; Stacey L Mueller-Ortiz; Rick A Wetsel
Journal:  Mol Immunol       Date:  2004-01       Impact factor: 4.407

5.  Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis.

Authors:  Laura Boos; Iain L Campbell; Robert Ames; Rick A Wetsel; Scott R Barnum
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

6.  Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism.

Authors:  J Leurs; V Nerme; Y Sim; D Hendriks
Journal:  J Thromb Haemost       Date:  2004-03       Impact factor: 5.824

7.  Familial carboxypeptidase N deficiency.

Authors:  K P Mathews; P M Pan; N J Gardner; T E Hugli
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

8.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

9.  The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.

Authors:  John B Walker; Laszlo Bajzar
Journal:  J Biol Chem       Date:  2004-05-05       Impact factor: 5.157

10.  Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.

Authors:  Timothy Myles; Toshihiko Nishimura; Thomas H Yun; Mariko Nagashima; John Morser; Andrew J Patterson; Ronald G Pearl; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2003-10-02       Impact factor: 5.157

View more
  1 in total

1.  Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course.

Authors:  Elia Gil-Varea; Elena Urcelay; Carles Vilariño-Güell; Carme Costa; Luciana Midaglia; Fuencisla Matesanz; Alfredo Rodríguez-Antigüedad; Jorge Oksenberg; Laura Espino-Paisan; A Dessa Sadovnick; Albert Saiz; Luisa M Villar; Juan Antonio García-Merino; Lluís Ramió-Torrentà; Juan Carlos Triviño; Ester Quintana; René Robles; Antonio Sánchez-López; Rafael Arroyo; Jose C Alvarez-Cermeño; Angela Vidal-Jordana; Sunny Malhotra; Nicolas Fissolo; Xavier Montalban; Manuel Comabella
Journal:  J Neuroinflammation       Date:  2018-09-14       Impact factor: 8.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.